SAGE Therapeutics (SAGE) Tops Q4 EPS by $18.54, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to SAGE Therapeutics (SAGE) Tops Q4 EPS by $18.54, Revenues Beat

Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

February 24, 2021 6:30 AM EST

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year

Progressed WATERFALL Study now closed to enrollment investigating zuranolone for as needed treatment of major depressive disorder with data anticipated in the first half of 2021

Entered into global collaboration with Biogen worth up to $3.1 billion, enabling planned expansion and acceleration of the Sage pipeline and increasing the potential patient reach to more than 450 million, if successful

... More